Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
The Canadian Journal of Urology
|
April 21, 2011
Updating the prostate cancer risk indicator for contemporary biopsy schemes
Meelan Bul, Nicolas B Delongchamps, Ewout W Steyerberg, et al.
Prostate Cancer and Prostatic Diseases
|
October 8, 2021
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
David F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
Prostate Cancer and Prostatic Diseases
|
December 1, 2021
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
David F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
BJU International
|
August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trial
Axel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
European Journal of Clinical Pharmacology
|
April 24, 2026
Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration
Tomoki Kojima, Masako Saito, Toshihiro Matsuda, et al.
European Urology Oncology
|
December 10, 2023
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis
Francisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, et al.
Future Oncology (London, England)
|
December 12, 2024
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Future Oncology (London, England)
|
June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
The Journal of Urology
|
December 28, 2020
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
The Journal of Urology
|
March 11, 2021
Reply by Authors
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
The Canadian Journal of Urology
|
April 21, 2011
Updating the prostate cancer risk indicator for contemporary biopsy schemes
Meelan Bul, Nicolas B Delongchamps, Ewout W Steyerberg, et al.
Prostate Cancer and Prostatic Diseases
|
October 8, 2021
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
David F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
Prostate Cancer and Prostatic Diseases
|
December 1, 2021
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
David F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
BJU International
|
August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trial
Axel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
European Journal of Clinical Pharmacology
|
April 24, 2026
Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration
Tomoki Kojima, Masako Saito, Toshihiro Matsuda, et al.
European Urology Oncology
|
December 10, 2023
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis
Francisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, et al.
Future Oncology (London, England)
|
December 12, 2024
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Future Oncology (London, England)
|
June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
The Journal of Urology
|
December 28, 2020
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
The Journal of Urology
|
March 11, 2021
Reply by Authors
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
Page
of 9